117 related articles for article (PubMed ID: 22728921)
1. Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminylphenol, a tyrosinase substrate, in melanoma models.
Ito S; Nishigaki A; Ishii-Osai Y; Ojika M; Wakamatsu K; Yamashita T; Tamura Y; Ito A; Honda H; Nakayama E; Jimbow K
Biochem Pharmacol; 2012 Sep; 84(5):646-53. PubMed ID: 22728921
[TBL] [Abstract][Full Text] [Related]
2. N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells.
Sato M; Yamashita T; Ohkura M; Osai Y; Sato A; Takada T; Matsusaka H; Ono I; Tamura Y; Sato N; Sasaki Y; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
J Invest Dermatol; 2009 Sep; 129(9):2233-41. PubMed ID: 19295615
[TBL] [Abstract][Full Text] [Related]
3. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity.
Gili A; Thomas PD; Ota M; Jimbow K
Melanoma Res; 2000 Feb; 10(1):9-15. PubMed ID: 10711635
[TBL] [Abstract][Full Text] [Related]
5. Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs.
Thomas PD; Kishi H; Cao H; Ota M; Yamashita T; Singh S; Jimbow K
J Invest Dermatol; 1999 Dec; 113(6):928-34. PubMed ID: 10594732
[TBL] [Abstract][Full Text] [Related]
6. Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release.
Sato A; Tamura Y; Sato N; Yamashita T; Takada T; Sato M; Osai Y; Okura M; Ono I; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
Cancer Sci; 2010 Sep; 101(9):1939-46. PubMed ID: 20594194
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.
Takada T; Yamashita T; Sato M; Sato A; Ono I; Tamura Y; Sato N; Miyamoto A; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
J Biomed Biotechnol; 2009; 2009():457936. PubMed ID: 19830247
[TBL] [Abstract][Full Text] [Related]
8. Oxidation of 4-alkylphenols and catechols by tyrosinase: ortho-substituents alter the mechanism of quinoid formation.
Krol ES; Bolton JL
Chem Biol Interact; 1997 Apr; 104(1):11-27. PubMed ID: 9158692
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and selective in vitro anti-melanoma effect of enantiomeric alpha-methyl- and alpha-ethyl-4-S-cysteaminylphenol.
Yukitake J; Otake H; Inoue S; Wakamatsu K; Olivares C; Solano F; Hasegawa K; Ito S
Melanoma Res; 2003 Dec; 13(6):603-9. PubMed ID: 14646624
[TBL] [Abstract][Full Text] [Related]
10. Tyrosinase-catalyzed metabolism of rhododendrol (RD) in B16 melanoma cells: production of RD-pheomelanin and covalent binding with thiol proteins.
Ito S; Okura M; Nakanishi Y; Ojika M; Wakamatsu K; Yamashita T
Pigment Cell Melanoma Res; 2015 May; 28(3):295-306. PubMed ID: 25713930
[TBL] [Abstract][Full Text] [Related]
11. [Development of targeted chemoradiotherapy for malignant melanoma by exploitation of metabolic pathway].
Jimbow K
Hokkaido Igaku Zasshi; 1998 Mar; 73(2):105-10. PubMed ID: 9612704
[TBL] [Abstract][Full Text] [Related]
12. A cell-based evaluation of human tyrosinase-mediated metabolic activation of leukoderma-inducing phenolic compounds.
Nishimaki-Mogami T; Ito S; Cui H; Akiyama T; Tamehiro N; Adachi R; Wakamatsu K; Ikarashi Y; Kondo K
J Dermatol Sci; 2022 Nov; 108(2):77-86. PubMed ID: 36567223
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.
Jimbow K; Ishii-Osai Y; Ito S; Tamura Y; Ito A; Yoneta A; Kamiya T; Yamashita T; Honda H; Wakamatsu K; Murase K; Nohara S; Nakayama E; Hasegawa T; Yamamoto I; Kobayashi T
J Skin Cancer; 2013; 2013():742925. PubMed ID: 23533767
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antimelanoma activity of sterically congested tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol.
Ferguson J; Rogers PM; Kelland LR; Robins DJ
Oncol Res; 2005; 15(2):87-94. PubMed ID: 16119006
[TBL] [Abstract][Full Text] [Related]
15. A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity.
Manini P; Napolitano A; Westerhof W; Riley PA; d'Ischia M
Chem Res Toxicol; 2009 Aug; 22(8):1398-405. PubMed ID: 19610592
[TBL] [Abstract][Full Text] [Related]
16. Dihydro-1,4-benzothiazine-6,7-dione, the ultimate toxic metabolite of 4-S-cysteaminylphenol and 4-S-cysteaminylcatechol.
Hasegawa K; Ito S; Inoue S; Wakamatsu K; Ozeki H; Ishiguro I
Biochem Pharmacol; 1997 May; 53(10):1435-44. PubMed ID: 9260870
[TBL] [Abstract][Full Text] [Related]
17. Antimelanoma effect of 4-S-cysteaminylcatechol, an activated form of 4-S-cysteaminylphenol.
Inoue S; Hasegawa K; Ito S; Ozeki H; Solano F; Jiménez-Cervantes C; Wakamatsu K; Fujita K
Cancer Res; 1995 Jun; 55(12):2603-7. PubMed ID: 7780975
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of selective toxicity of 4-S-cysteinylphenol and 4-S-cysteaminylphenol to melanocytes.
Ito S; Kato T; Ishikawa K; Kasuga T; Jimbow K
Biochem Pharmacol; 1987 Jun; 36(12):2007-11. PubMed ID: 3109434
[TBL] [Abstract][Full Text] [Related]
19. Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3-iodobenzene, a novel melanin precursor, in melanogenic melanoma cells.
Prezioso JA; Damodaran KM; Wang N; Bloomer WD
Biochem Pharmacol; 1993 Jan; 45(2):473-81. PubMed ID: 8435097
[TBL] [Abstract][Full Text] [Related]
20. Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis.
Minamitsuji Y; Toyofuku K; Sugiyama S; Yamada K; Jimbow K
J Investig Dermatol Symp Proc; 1999 Sep; 4(2):130-6. PubMed ID: 10536987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
